The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Open accessAbstract
The emergence of antimicrobial resistance is a significant public health issue worldwide, particularly for healthcare-associated infections caused by carbapenem-resistant gram-negative pathogens. Cefiderocol is a novel siderophore cephalosporin targeting gram-negative bacteria, including strains with carbapenem resistance. The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to withstand hydrolysis by β-lactamases. The unique chemical component is the addition of a catechol moiety on the C-3 side chain, which chelates iron and mimics naturally occurring siderophore molecules. Following the chelation of iron, cefiderocol is actively transported across the outer membrane of the bacterial cell to the periplasmic space via specialized iron transporter channels. Furthermore, cefiderocol has demonstrated structural stability against hydrolysis by both serine- and metallo-β-lactamases, including clinically relevant carbapenemases such as Klebsiella pneumoniae carbapenemase, oxacillin carbapenemase-48, and New Delhi metallo-β-lactamase. Cefiderocol has demonstrated promising in vitro antibacterial and bactericidal activity, which correlates with its in vivo efficacy in several animal models. This article reviews the discovery and chemistry of cefiderocol, as well as some of the key microbiological and in vivo findings on cefiderocol from recently conducted investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Weinstein, M. P., & Clinical (2019) · Clinical and Laboratory Standards Institute eBooks · Cited by 4,341
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
Siderophores in Iron Metabolism: From Mechanism to Therapy Potential
Wilson, B. R., Bogdan, A. R., Miyazawa, M., Hashimoto, K., & Tsuji, Y. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.005 · Cited by 477
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Self-citationIto, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Self-citationTsai, Y.-K., Fung, C.-P., Lin, J.-C., Chen, J.-H., Chang, F.-Y., Chen, T.-L., & Siu, L. K. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01275-10 · Cited by 344
Carbapenem-Resistant Enterobacteriaceae
Iovleva, A., & Doi, Y. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.01.005 · Cited by 263
The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
Page, M. G. P. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz825 · Cited by 245
Sideromycins: tools and antibiotics
Braun, V., Pramanik, A., Gwinner, T., Köberle, M., & Bohn, E. (2009) · BioMetals · doi:10.1007/s10534-008-9199-7 · Cited by 236
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., & Tateda, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03098-15 · Cited by 187
Self-citationAoki, T., Yoshizawa, H., Yamawaki, K., Yokoo, K., Sato, J., Hisakawa, S., Hasegawa, Y., Kusano, H., Sano, M., Sugimoto, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.014 · Cited by 172
Self-citationExploiting Bacterial Iron Acquisition: Siderophore Conjugates
Ji, C. Y., Juárez-Hernández, R. E., & Miller, M. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.191 · Cited by 165
Page, M. G. P. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12024 · Cited by 136
Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., Karlowsky, J. A., & Sahm, D. F. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.03.003 · Cited by 133
Moynié, L., Lüscher, A., Rolo, D., Pletzer, D., Tortajada, A., Weingart, H., Braun, Y., Page, M. G. P., Naismith, J. H., & Köhler, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02531-16 · Cited by 131
Nakamura, R., Ito-Horiyama, T., Takemura, M., Toba, S., Matsumoto, S., Ikehara, T., Tsuji, M., Sato, T., & Yamano, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-18 · Cited by 119
Self-citationPharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
Katsube, T., ECHOLS, R. M., & Wajima, T. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz828 · Cited by 114
Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
Tomaras, A. P., Crandon, J. L., McPherson, C. J., Banevicius, M. A., Finegan, S. M., Irvine, R. L., Brown, M. F., O'Donnell, J. P., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-13 · Cited by 110
McPherson, C. J., Aschenbrenner, L. M., Lacey, B. M., Fahnoe, K. C., Lemmon, M. M., Finegan, S. M., Tadakamalla, B., O'Donnell, J. P., Mueller, J. P., & Tomaras, A. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01345-12 · Cited by 91
Iron transport-mediated drug delivery using mixed-ligand siderophore-β-lactam conjugates
Ghosh, A. K., Ghosh, M., Niu, C., Malouin, F., Moellmann, U., & Miller, M. J. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90167-2 · Cited by 89
Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00831-15 · Cited by 82
Ito, A., Nishikawa, T., Oota, M., Ito-Horiyama, T., Ishibashi, N., Sato, T., Tsuji, M., & Yamano, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky317 · Cited by 74
Self-citationSilley, P., Griffiths, J., Monsey, D., & Harris, A. M. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.9.1806 · Cited by 71
Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
Poirel, L., Kieffer, N., & Nordmann, P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.005 · Cited by 58
Brochu, A., Brochu, N., Nicas, T. I., Parr, T. R., Minnick, A. A., Dolence, E. K., McKee, J. A., Miller, M. J., Lavoie, M. C., & Malouin, F. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2166 · Cited by 57
Bactericidal activity of M14659 enhanced in low-iron environments
Mochizuki, H., Yamada, H., Oikawa, Y., Murakami, K., Ishiguro, J., Kosuzume, H., AIZAWA, N., & Mochida, E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.11.1648 · Cited by 54
Ghazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.10.008 · Cited by 54
Diarra, M. S., Lavoie, M. C., Jacques, M., Darwish, I. S., Dolence, E. K., Dolence, J. A., Ghosh, A. K., Ghosh, M., Miller, M. J., & Malouin, F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2610 · Cited by 50
Ghazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2018) · Pharmacology · doi:10.1159/000487441 · Cited by 41
Huband, M. D., Ito, A., Tsuji, M., Sader, H. S., Fedler, K. A., & Flamm, R. K. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.03.011 · Cited by 39
Mushtaq, S., Woodford, N., Hope, R., Adkin, R., & Livermore, D. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt050 · Cited by 37
Antibacterial activity of BMS-180680, a new catechol-containing monobactam
Fung-Tomc, J. C., Bush, K., Minassian, B., Kolek, B., Flamm, R. K., Gradelski, E., & BONNER, D. P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1010 · Cited by 35
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Ito, A., Nishikawa, T., Ishii, R., Kuroiwa, M., Ishioka, Y., Kurihara, N., Sakikawa, I., Ota, T., Rokushima, M., Tsuji, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.703 · Cited by 29
Self-citationKanazawa, S., Sato, T., Kohira, N., Ito-Horiyama, T., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00576-17 · Cited by 17
Self-citationYamano, Y., Nishikawa, T., & Komatsu, Y. (1994) · Applied Microbiology and Biotechnology · doi:10.1007/bf00173995 · Cited by 11
Cited by
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
Terreni, M., Taccani, M., & Pregnolato, M. (2021) · Molecules · doi:10.3390/molecules26092671 · Cited by 596
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 300
Metadata
- Authors
- Sato, T., & Yamawaki, K.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-13
- Volume
- 69
- Issue
- Supplement_7
- Pages
- S538-S543
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2987552683
- Cited by
- 379
- References
- 37
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.